Doris M. Ponce, MD

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects.

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.

Supportive care measures for acute GvHD are explored, highlighting strategies to manage symptoms and improve patient well-being.

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment.

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.